UNSPSC 51431902: Telmisartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C33H30N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U5SYW473RQ, chemically known as (1,1-biphenyl)-2-carboxylic acid, 4-((1,4-dimethyl-2-propyl(2,6-bi-1h-benzimidazol)-1-yl)methyl)- but generally known as telmisartan, which bears US NIH Compound Identifier 65999. European Medicines Agency schedules Telmisartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10874MIG.

UNSPSC 51431902 Telmisartan is a Commodity code representing individual pharmaceutical products procured by state and local health agencies, emergency response services, and multi-state cooperative purchasing alliances. State and local governments use this code to acquire specific branded or generic medications for use in hospital systems, fire rescue departments, state health and human services programs, and cooperative purchasing networks spanning multiple jurisdictions. The issuing bodies soliciting under this code include municipal purchasing departments (city fire rescue services), state health and human services agencies, and regional multi-state cooperative purchasing alliances that coordinate procurement across member states and localities.

Recent activity shows the City of Tampa's Purchasing Department soliciting Advanced Life Support Medications (Bid No. 26-P-00188, IFB, due April 8, 2026) for Tampa Fire Rescue in Hillsborough County, Florida, requesting four medication line items with firm pricing, nine-month minimum expiration dates, and a one-year contract term with renewal options; the Texas Health and Human Services Commission issuing RFI No. HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posting RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities in Minnesota and Oregon, with contract award effective July 1, 2026. Geographic activity centers on Florida, Texas, and Minnesota with multi-state reach through cooperative purchasing mechanisms. The MMCAP solicitation reflects the largest geographic scope, distributing products through authorized wholesalers across multiple jurisdictions, while the Tampa and Texas opportunities show direct state and local government engagement with individual product categories and program structures.